MYK-224
MYK-224 is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy.[1][2][3]
MYK-224 is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy.[1][2][3]
This article uses material from the Wikipedia article MYK-224, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.